Filing Flows › Health Care › aTYR Pharma (ATYR)
aTYR Pharma (ATYR) earnings and revenue breakdown
Latest: Q3 2025 · 10-Q filed Nov 6, 2025 · aTYR Pharma (ATYR) Q3 2025 earnings results →
aTYR Pharma made $190K in Q3 2025. Operating margin n/m, net loss $25.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $190K in Q3 2025.
Operating costs exceeded revenue by $26.7M, an operating margin of -14076.3%. The quarter ended with a net loss of $25.7M. Minority interests bore $2K of it: to shareholders the quarter was a loss of $25.7M.
Operating cash flow was −$20.5M. Non-cash charges added back $165K of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items added $3.8M. Capital expenditures of $37K exceeded it, leaving free cash flow of −$20.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2025 | 10-Q | Nov 6, 2025 | $190K | — | n/m | −$25.7M | −$20.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About aTYR Pharma
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com .
In its own words, from its 8-K, filed Aug 7, 2026.
aTYR Pharma against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ATYR aTYR Pharma | Q3 2025 | $190K | — | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: aTYR Pharma 10-Q on SEC EDGAR · CIK 1339970 · Biological Products, (No Diagnostic Substances)
13F: who owns ATYR and who is buying
More on ATYR
History
Every quarter: Q3 2025 results